Van Hulzen Asset Management LLC Has $723,000 Holdings in Cencora, Inc. $COR

Key Points

• Van Hulzen Asset Management LLC reduced its stake in Cencora, Inc. by 90.3%, leaving it with 2,601 shares valued at $723,000 as of the latest SEC filing.
• Cencora recently announced a quarterly dividend of $0.55 per share, with an ex-dividend date set for August 15th, reflecting an annualized yield of 0.8%.
• Insider transactions include CEO Robert P. Mauch's sale of 4,968 shares for approximately $1.46 million, representing a 10.5% decrease in his ownership of the stock.

Van Hulzen Asset Management LLC trimmed its stake in Cencora, Inc. (NYSE:COR - Free Report) by 90.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,601 shares of the company's stock after selling 24,325 shares during the period. Van Hulzen Asset Management LLC's holdings in Cencora were worth $723,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Cornerstone Planning Group LLC lifted its stake in shares of Cencora by 106.7% in the first quarter. Cornerstone Planning Group LLC now owns 93 shares of the company's stock valued at $26,000 after buying an additional 48 shares during the period. Hoey Investments Inc. bought a new position in Cencora during the first quarter valued at about $28,000. Costello Asset Management INC acquired a new position in Cencora in the 1st quarter valued at approximately $28,000. Banque Transatlantique SA bought a new stake in shares of Cencora in the 4th quarter worth approximately $29,000. Finally, Vermillion Wealth Management Inc. bought a new stake in shares of Cencora in the 4th quarter worth approximately $38,000. Institutional investors own 97.52% of the company's stock.

Insider Buying and Selling

In other news, CEO Robert P. Mauch sold 4,968 shares of the stock in a transaction on Friday, July 18th. The stock was sold at an average price of $294.11, for a total transaction of $1,461,138.48. Following the sale, the chief executive officer owned 42,351 shares in the company, valued at approximately $12,455,852.61. This represents a 10.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven H. Collis sold 14,578 shares of the firm's stock in a transaction on Tuesday, July 22nd. The shares were sold at an average price of $292.67, for a total value of $4,266,543.26. Following the completion of the sale, the chairman owned 309,913 shares of the company's stock, valued at approximately $90,702,237.71. This trade represents a 4.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,125 shares of company stock worth $9,993,789. 10.80% of the stock is owned by corporate insiders.

Cencora Trading Down 3.6%

Shares of Cencora stock opened at $292.2490 on Friday. The stock has a market capitalization of $56.66 billion, a P/E ratio of 30.07, a price-to-earnings-growth ratio of 1.44 and a beta of 0.58. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. The company has a 50-day simple moving average of $293.48 and a 200 day simple moving average of $280.44. Cencora, Inc. has a 12-month low of $218.65 and a 12-month high of $309.35.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.21. The firm had revenue of $80.66 billion during the quarter, compared to the consensus estimate of $80.34 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm's quarterly revenue was up 8.7% on a year-over-year basis. During the same period last year, the firm posted $3.34 EPS. Research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, August 15th will be given a dividend of $0.55 per share. The ex-dividend date is Friday, August 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.8%. Cencora's dividend payout ratio is 22.63%.

Wall Street Analyst Weigh In

COR has been the topic of a number of research reports. UBS Group boosted their price objective on Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. Wells Fargo & Company boosted their price target on shares of Cencora from $337.00 to $354.00 and gave the company an "overweight" rating in a report on Wednesday, August 13th. Jefferies Financial Group increased their price objective on shares of Cencora from $275.00 to $300.00 and gave the company a "hold" rating in a research note on Monday, June 30th. Morgan Stanley set a $330.00 price objective on shares of Cencora and gave the stock an "equal weight" rating in a report on Wednesday, July 16th. Finally, Citigroup lifted their target price on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $311.25.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.